Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 - (ACN Newswire via SEAPRWire.com) - Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational...

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

TOKYO and CAMBRIDGE, Mass., May 10, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational...

Project Management Institute’s New PMP® Exam Prep Companion PMI Study Hall™ Joins BenchPrep’s Learning Platform

CHICAGO, April 27, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) -- Project Management Institute (PMI), the world’s leading association for project management, is turning to BenchPrep’s award-winning professional learning platform to host PMI Study Hall™, a “study companion” program for the Project Management Professional (PMP)® certification. PMI Study Hall helps prepare candidates...

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

TOKYO, Mar 4, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril...

Covid may harm testicles, cut sex drive: HKU study

Research by the University of Hong Kong indicates that Covid-19 could damage testicles and lead to low sex drive and reduced fertility. A team of microbiologist led by Professor Yuen Kwok-yung based the findings on a study of testicular and hormonal changes in hamsters infected by the coronavirus. The infected...

‘Govt should study whether CE polls should go ahead’

Hong Kong's sole delegate to the nation's top legislative body, Tam Yiu-chung, said on Thursday that authorities should study whether next month's chief executive election should go ahead in view of the coronavirus outbreaks. Tam Yiu-chung of the National People's Congress Standing Committee told a Commercial Radio programme that containing...

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased...

HKers must study historic resolution: Paul Chan

Financial Secretary Paul Chan said Hong Kong people must study the historic resolution adopted at the recent Communist Party plenum, saying it is vital to the country and Hong Kong's future. Writing on his blog, he said a "strong leadership core" has been behind the success of the party, and...

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild...

Eisai: Introduction of Plasma-based Biomarker Screening to Facilitate Identification of Subjects for Phase 3 Ahead 3-45 Trial Presented at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Nov 12, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and Biogen Inc. announced a presentation about exploring the use of plasma-based biomarkers in the Phase 3 AHEAD 3-45 study of lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody. AHEAD 3-45 is the...

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

TOKYO, Nov 9, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, has an agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency...

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

HONG KONG, Sep 17, 2021 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") to out-license the right to develop and commercialize SN1011...

Toyota: Feasibility Study on the Receiving and Distribution Business of Imported Hydrogen in Chubu Regio

Toyota City, Japan, Aug 6, 2021 - (JCN Newswire via SEAPRWire.com) - Sumitomo Corporation, Chiyoda Corporation, Toyota Motor Corporation, Japan Research Institute, Limited, and Sumitomo Mitsui Banking Corporation (collectively, "Joint Contractors") have been appointed by the New Energy and Industrial Technology Development Organization ("NEDO") to conduct a feasibility study on...